|Title:||The chinese medtech sector with focus on new regulatory rules|
|Authors :||Mattes, Urs|
|Publisher / Ed. Institution :||Switzerland Global Enterprise|
|Publisher / Ed. Institution:||Zürich|
|License (according to publishing contract) :||Licence according to publishing contract|
|Subjects :||Chinese Medtech; Switzerland global enterprise; Regulatory rule; Healthcare|
|Subject (DDC) :||362: Health and social services|
|Abstract:||Even though 95 per cent of the population is insured by basic medical insurance, the scheme does not address chronically ill patients who need long term treatment. China spends 5.8 per cent of its GDP on healthcare and the per capita expenditure is US$ 650, which is inadequate to provide for chronically ill patients. Since there is no gatekeeper in the Chinese healthcare system, the government is trying to channel patients to community health centers. The development of the private healthcare market is slow, because most doctors do not want to leave careers at public hospitals. Outbound medical tourism has reached a size of US$ 10 billion in 2015, as affluent people tend to avoid treatment in China. It seems obvious that in the future two different healthcare systems will coexist in China, namely: a large high-volume, low-priced public system and a small low-volume, high-priced private system. Since the large public system is controlled by the government, tender prices are bound to get lower.|
|Departement:||School of Management and Law|
|Organisational Unit:||Institute of Marketing Management (IMM)|
|Publication type:||Working paper – expertise – study|
|Appears in Collections:||Publikationen School of Management and Law|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.